THC Tolerance Resolved Differently for Urine Output and Pain Responses in Mice
Recovery from THC tolerance differed between urine-output and antinociceptive effects in a mouse experiment. The result argues against assuming that every physiological response returns to baseline on one abstinence timetable.
Researchers measured dose-response relationships
Mice received repeated THC, with cannabinoid dose-response testing before treatment and after discontinuation. The study examined THC and AM4054 and included comparisons with a kappa-opioid agonist and furosemide.
The diuretic response was not a drug test
The outcome was the quantity of urine produced, not the concentration of THC metabolites in a urine specimen. These measurements answer fundamentally different questions. A change in urine output cannot establish a cannabis detection window.
Recovery and cross-tolerance were selective
The abstract reports cannabinoid diuretic effects returning near baseline within fourteen days, while antinociceptive tolerance persisted longer. The kappa-opioid agonist's diuretic effect was attenuated after repeated THC, whereas furosemide's effect was unchanged.
That unchanged comparison helps constrain a claim of generalized suppression of all urine-producing responses. The study also reported reduced CB1 receptor binding capacity, a tissue-binding result rather than a forensic impairment threshold. Species, repeated injected exposure and selected endpoints limit translation. These data do not establish a human tolerance-break length, a urine-test clearance rule or preserved performance during daily cannabis use.
Related: interpreting cannabis tolerance claims.
Research cited
Chopda GR; Parge V; Thakur GA; Gatley SJ; Makriyannis A; Paronis CA. Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice. The Journal of pharmacology and experimental therapeutics (2016). doi:10.1124/jpet.116.232132. Findings discussed from the study abstract.
